Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hellmuth-Alexander Meyer

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Urology|August 11, 2007
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populationsCarsten Stephan, Chuanliang Xu, Patrik Finne, et al.
Plos One|February 10, 2016
Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5pZofia Wotschofsky, Linda Gummlich, Julia Liep, et al.
The Journal of Urology|October 23, 2012
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosisJonas Busch, Kristin Hamborg, Hellmuth-Alexander Meyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2011
Effects of systemic versus local administration of corticosteroids on mucosal toleranceJerome Kerzerho, Daniela Wunsch, Natacha Szely, et al.
BJU International|March 16, 2007
Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsiesCarsten Stephan, Jürgen Kramer, Hellmuth-Alexander Meyer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
Reduced serum selenoprotein P concentrations in German prostate cancer patientsHellmuth-Alexander Meyer, Birgit Hollenbach, Carsten Stephan, et al.
Clinical Chemistry|May 26, 2011
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomogramsCarsten Stephan, Kerstin Siemssen, Henning Cammann, et al.
Plos One|June 30, 2012
Reference miRNAs for miRNAome analysis of urothelial carcinomasNadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
BMC Cancer|December 18, 2008
The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancerAchim Weber, Ilka Kristiansen, Manfred Johannsen, et al.
The Journal of Molecular Diagnostics : JMD|August 16, 2013
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcomeNadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Urology|August 11, 2007
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populationsCarsten Stephan, Chuanliang Xu, Patrik Finne, et al.
Plos One|February 10, 2016
Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5pZofia Wotschofsky, Linda Gummlich, Julia Liep, et al.
The Journal of Urology|October 23, 2012
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosisJonas Busch, Kristin Hamborg, Hellmuth-Alexander Meyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2011
Effects of systemic versus local administration of corticosteroids on mucosal toleranceJerome Kerzerho, Daniela Wunsch, Natacha Szely, et al.
BJU International|March 16, 2007
Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsiesCarsten Stephan, Jürgen Kramer, Hellmuth-Alexander Meyer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
Reduced serum selenoprotein P concentrations in German prostate cancer patientsHellmuth-Alexander Meyer, Birgit Hollenbach, Carsten Stephan, et al.
Clinical Chemistry|May 26, 2011
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomogramsCarsten Stephan, Kerstin Siemssen, Henning Cammann, et al.
Plos One|June 30, 2012
Reference miRNAs for miRNAome analysis of urothelial carcinomasNadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
BMC Cancer|December 18, 2008
The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancerAchim Weber, Ilka Kristiansen, Manfred Johannsen, et al.
The Journal of Molecular Diagnostics : JMD|August 16, 2013
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcomeNadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
Pageof 3